Restoring youth from the source
A 29-residue GHRH analog that prompts the pituitary to release endogenous growth hormone.
Educational content. This page describes Sermorelin for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Sermorelin (GHRH(1-29)NH2) is a synthetic 29-amino acid peptide corresponding to the first 29 amino acids of human GHRH. It is the shortest fragment retaining full biological activity. FDA-approved in 1997 (Geref) for diagnosing and treating pediatric GH deficiency.
Widely used off-label in adults to restore age-related GH decline. Because it stimulates the body's own GH production, it preserves natural feedback regulation and pulsatile secretion, a significant advantage over direct GH injection.
Sermorelin binds GHRH receptors on pituitary somatotrophs, triggering GH synthesis and secretion. Released GH stimulates hepatic IGF-1 production for downstream tissue and metabolic effects.
A critical advantage: the GH release is still modulated by somatostatin, preventing supraphysiological levels. This self-limiting mechanism makes sermorelin safer for long-term use than direct GH injection.
Administered at bedtime, sermorelin augments the natural nocturnal GH surge. Over time, it may exert trophic effects on pituitary somatotrophs, restoring GH secretory capacity.
Restoring youth from the source
Sermorelin binds GHRH receptors on pituitary somatotrophs, triggering GH synthesis and pulsatile release through the same physiological pathway as endogenous GHRH. Natural somatostatin feedback prevents supraphysiological elevation. Bedtime dosing amplifies the nocturnal GH surge and may restore age-diminished pituitary capacity.
Key studies supporting the therapeutic use of this peptide.
Increased nocturnal GH and IGF-1, skin thickness, lean body mass, insulin sensitivity, well-being, and libido in men.
Khorram O, Laughlin GA, Yen SS — J Clin Endocrinol Metab, 82(5):1472-1479 (1997) · PubMed
30% B cell increase, 50% mitogen responsiveness increase, 70% IL-2 receptor-expressing lymphocytes increase.
Khorram O, Yeung M, Vu L, Yen SS — J Clin Endocrinol Metab, 82(11):3590-3596 (1997) · PubMed
Nearly doubled height velocity from 4.1 to 8.0 cm/year at 6 months. 74% good response.
Thorner M, Rochiccioli P, Colle M, et al. — J Clin Endocrinol Metab, 81(3):1189-1196 (1996) · PubMed
Typical protocols used in clinical practice. Always consult a licensed provider for personalized dosing.
Subcutaneous (adults)
Subcutaneous (pediatric, FDA-approved)
Subcutaneous (adults): Bedtime on empty stomach (2-3 hours after eating)
Subcutaneous (pediatric, FDA-approved): FDA-approved dosing for GH-deficient children
Bedtime administration is essential to maximize synergy with the natural nocturnal GH surge. Empty stomach required.
Effects are cumulative; may take 3-6 months to become clinically apparent.
Periodic IGF-1 monitoring recommended to guide dosing.
One of the most documented safety profiles among GH peptides, owing to FDA approval history and multicenter trials. No adverse biochemical or hormonal changes in 110-child study over 12 months.
Key safety advantage: somatostatin feedback prevents supraphysiological GH levels, avoiding the significant side effects of direct GH therapy.
Transient facial flushing and injection site discomfort are the most common adverse events.
See how Sermorelin compares to peptides with overlapping benefits.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| Sermorelin | Anti-Aging & GH Restoration | Injection (daily) | 3–6 months | Only GHRH analog with FDA approval history and multi-decade safety record, uniquely preserving natural GH feedback |
| SS-31 (Elamipretide) | Mitochondrial Restoration & Anti-Aging | Injection (daily) | Continuous (weeks to months) | Only peptide that directly targets cardiolipin on the inner mitochondrial membrane to restore electron transport chain efficiency |
| Tesamorelin | Body Composition & GHRH | Subcutaneous Injection | Ongoing daily | The only FDA-approved GHRH analog with Phase III data in over 800 patients, proven hepatoprotective effects, and physiologic pulsatile GH release |
| GHK-Cu | Anti-Aging & Recovery | Topical, Injection | 8–12 weeks | Only peptide demonstrated to modulate ~31% of human genes, epigenetically resetting cellular function toward a younger phenotype |
| Glutathione | Antioxidant & Detoxification | IV, Oral, Sublingual | Ongoing supplementation | The body's own master antioxidant, with clinical data supporting oral bioavailability (challenging earlier assumptions) and dramatic immune cell activation at high doses |
Current FDA classification and compounding eligibility.
This substance is in Category 1 of the FDA's 503A bulk drug substances evaluation. Licensed 503A pharmacies may compound it under FDA enforcement discretion while the agency continues its review.
Previously FDA-approved as Geref (NDA 020443) for pediatric growth hormone deficiency. Discontinued by the manufacturer in 2008 for commercial reasons, not safety concerns. Compoundable under the 'component of FDA-approved drug' pathway: because sermorelin was previously an approved drug, 503A pharmacies may compound it without it appearing on the interim Category 1 list.
Manufacturer discontinued Geref (sermorelin acetate, NDA 020443) for commercial reasons
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into Sermorelin? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA mitochondria-targeted tetrapeptide that stabilizes cardiolipin to support cellular energy.
FDA-approved as Forzinity for Barth syndrome in 2025; the first mitochondria-targeted therapeutic approved.
A tripeptide-copper complex that supports skin regeneration and wound healing.
Naturally occurring in plasma; levels decline with age. Widely used in topical and compounded formulations.
A tripeptide antioxidant central to cellular redox, detoxification, and immune function.
Produced endogenously and supplemented via IV, injection, or oral routes; clinical evidence remains mixed.